SCHEMBL6769646

SCHEMBL6769646

CCOC(=O)CC(CS(=O)(=O)c1cccc(OC)c1)c1ccc(F)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.44
TSHR P16473 2/20 0.41
LMNA P02545 1/20 0.41
GLA P06280 1/20 0.41
HTT P42858 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
GPR183 P32249 1/20 0.41
HPGD P15428 1/20 0.40
PKM P14618 1/20 0.40
GAA P10253 1/20 0.39
HSD11B1 P28845 1/20 0.38
F2 P00734 1/20 0.38
F10 P00742 1/20 0.38
ALDH1A1 P00352 3/20 0.38
MEP1B Q16820 1/20 0.38
MAPK1 P28482 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
MGLL Q99685 1/20 0.38
MAPT P10636 2/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6771823 0.87 F10 (0.39) KMT2ALMNAHTTHPGDGAA
SCHEMBL6772429 0.87 KMT2A (0.47) KMT2ALMNAHTTGPR183HPGD
SCHEMBL6774874 0.77 F10 (0.43) KMT2ATSHRGAAHSD11B1F2
SCHEMBL7566284 0.73 F2 (0.48) KMT2ALMNAHTTHPGDGAA
SCHEMBL7079059 0.72 ALDH1A1 (0.45) KMT2ALMNAHTTHSD11B1ALDH1A1
SCHEMBL10665829 0.71 L3MBTL1 (0.56) KMT2AGLAHTTHPGDF2
SCHEMBL4115797 0.71 L3MBTL1 (0.52) TSHRALDH1A1MAPK1TDP1L3MBTL1
SCHEMBL7566821 0.70 F2 (0.52) KMT2ALMNAHTTHPGDGAA
SCHEMBL1369571 0.70 L3MBTL1 (0.52) TSHRGAAF2F10ALDH1A1
SCHEMBL6896597 0.70 MAPT (0.60) KMT2ALMNAHPGDPKMGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6833366-B1 Dihydrostilbene alkanoic acid derivatives PHARMACIA CORPORATION 2004-12-21 US disclosed
US-6720315-B2 FOR INHIBITING BONE RESORPTION, PERIODONTAL DISEASE, OSTEOPOROSIS, HUMORAL HYPERCALCEMIA OF MALIGNANCY, PAGET'S DISEASE, TUMOR METASTASIS, SOLID TUMOR GROWTH, ANGIOGENESIS, MACULAR DEGENERATION AND DIABETIC RETINOPATHY RETINOPATHY PHARMACIA CORPORATION 2004-04-13 US disclosed
EP-1289959-A1 DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS Pharmacia Corporation (US) 2003-03-12 EP disclosed
US-20020099209-A1 Dihydrostilbene alkanoic acid derivatives PHARMACIA CORPORATION 2002-07-25 US disclosed
WO-2001096310-A1 DIHYDROSTILBENE ALKANOIC ACID DERIVATIVES USEFUL AS VITRONECTIN ANTAGONISTS PHARMACIA CORPORATION (US) 2001-12-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020099209-A1 Dihydrostilbene alkanoic acid derivatives ITGA5, ITGB5, ITGB1 KMT2A 3377/4885TSHR 3106/4885LMNA 2008/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.